Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q13409
UPID:
DC1I2_HUMAN
Alternative names:
Cytoplasmic dynein intermediate chain 2; Dynein intermediate chain 2, cytosolic
Alternative UPACC:
Q13409; B7ZA04; D3DPD4; D3DPD5; D3DPD6; Q32LY9; Q53S84; Q5BJF8; Q7Z4X1; Q96NG7; Q96S87; Q9BXZ5; Q9NT58
Background:
Cytoplasmic dynein 1 intermediate chain 2, also known as Dynein intermediate chain 2, cytosolic, plays a crucial role in the cytoplasmic dynein 1 complex. This protein is essential for the retrograde motility of vesicles and organelles along microtubules, facilitating processes such as membrane transport to the Golgi apparatus, late endosomes, and lysosomes. Its interaction with the dynactin complex through the p150-glued component is vital for dynein function.
Therapeutic significance:
The protein is linked to a neurodevelopmental disorder characterized by microcephaly and structural brain anomalies, highlighting its importance in brain development. Understanding the role of Cytoplasmic dynein 1 intermediate chain 2 could open doors to potential therapeutic strategies for treating such neurodevelopmental disorders.